Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282037505> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4282037505 endingPage "9001" @default.
- W4282037505 startingPage "9001" @default.
- W4282037505 abstract "9001 Background: While existing data suggest a detriment of immune checkpoint inhibitors (ICI) in other targetable mutations in non-small cell lung cancer (NSCLC), limited retrospective analyses suggest patients with Kirsten rat sarcoma oncogene ( KRAS)-mutated NSCLC benefit from ICI in the front-line (1L). To better define this benefit, pooled data from 12 registrational clinical trials investigating 1L ICI with or without chemotherapy (chemo) in patients with documented KRAS status (mutant or wildtype) was evaluated for efficacy of ICI+chemo, ICI alone, and chemo alone. Methods: Pooled data was evaluated for objective response rate (ORR) and overall survival (OS) by KRAS status (mutant, G12C, or wildtype). ORR and 95% confidence intervals (CI) were estimated using Clopper-Pearson method; median OS was estimated using Kaplan-Meier methods. Subgroup analyses were performed using Cox model stratified by KRAS status and PD-L1 status (Positive (combined positive score (CPS) ≥1), Negative (CPS<1), High (CPS≥50), Low (CPS<50)). Results: KRAS mutational status was reported in 1430 patients (61% wildtype, 39% mutated). KRAS G12C was reported in 11% of patients with a KRAS mutation (157/555). Demographics were similar between KRAS mutated, G12C, and wildtype patients. Amongst all patients, 60% were male, 89% white, 60% positive PD-L1, 67% former or current smokers. Table 1 shows outcomes of chemo+ICI, ICI alone, and chemo alone in each population. Conclusions: This retrospective, pooled analysis suggests that patients with KRAS-mutated NSCLC benefit from 1L chemo-ICI similarly to those with KRAS wild-type NSCLC, and should receive combination therapy upfront. Patients with KRAS-mutated NSCLC derived the greatest benefit from the combination of chemo-ICI as compared to ICI or chemo alone. The small number of patients with documented KRAS G12C mutation limits interpretation of the data for this subgroup. Clinical trials investigating targeted therapies for KRAS-mutated NSCLC in the 1L should include a chemo-ICI comparator arm. [Table: see text]" @default.
- W4282037505 created "2022-06-13" @default.
- W4282037505 creator A5004000071 @default.
- W4282037505 creator A5035436218 @default.
- W4282037505 creator A5038644290 @default.
- W4282037505 creator A5043067852 @default.
- W4282037505 creator A5049770941 @default.
- W4282037505 creator A5051520990 @default.
- W4282037505 creator A5063991986 @default.
- W4282037505 creator A5064298075 @default.
- W4282037505 creator A5070924546 @default.
- W4282037505 creator A5074141991 @default.
- W4282037505 creator A5079743886 @default.
- W4282037505 date "2022-06-01" @default.
- W4282037505 modified "2023-09-29" @default.
- W4282037505 title "Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis." @default.
- W4282037505 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.9001" @default.
- W4282037505 hasPublicationYear "2022" @default.
- W4282037505 type Work @default.
- W4282037505 citedByCount "14" @default.
- W4282037505 countsByYear W42820375052022 @default.
- W4282037505 countsByYear W42820375052023 @default.
- W4282037505 crossrefType "journal-article" @default.
- W4282037505 hasAuthorship W4282037505A5004000071 @default.
- W4282037505 hasAuthorship W4282037505A5035436218 @default.
- W4282037505 hasAuthorship W4282037505A5038644290 @default.
- W4282037505 hasAuthorship W4282037505A5043067852 @default.
- W4282037505 hasAuthorship W4282037505A5049770941 @default.
- W4282037505 hasAuthorship W4282037505A5051520990 @default.
- W4282037505 hasAuthorship W4282037505A5063991986 @default.
- W4282037505 hasAuthorship W4282037505A5064298075 @default.
- W4282037505 hasAuthorship W4282037505A5070924546 @default.
- W4282037505 hasAuthorship W4282037505A5074141991 @default.
- W4282037505 hasAuthorship W4282037505A5079743886 @default.
- W4282037505 hasConcept C121608353 @default.
- W4282037505 hasConcept C126322002 @default.
- W4282037505 hasConcept C143998085 @default.
- W4282037505 hasConcept C187960798 @default.
- W4282037505 hasConcept C2776907518 @default.
- W4282037505 hasConcept C2781187634 @default.
- W4282037505 hasConcept C2908647359 @default.
- W4282037505 hasConcept C44249647 @default.
- W4282037505 hasConcept C526805850 @default.
- W4282037505 hasConcept C71924100 @default.
- W4282037505 hasConcept C99454951 @default.
- W4282037505 hasConceptScore W4282037505C121608353 @default.
- W4282037505 hasConceptScore W4282037505C126322002 @default.
- W4282037505 hasConceptScore W4282037505C143998085 @default.
- W4282037505 hasConceptScore W4282037505C187960798 @default.
- W4282037505 hasConceptScore W4282037505C2776907518 @default.
- W4282037505 hasConceptScore W4282037505C2781187634 @default.
- W4282037505 hasConceptScore W4282037505C2908647359 @default.
- W4282037505 hasConceptScore W4282037505C44249647 @default.
- W4282037505 hasConceptScore W4282037505C526805850 @default.
- W4282037505 hasConceptScore W4282037505C71924100 @default.
- W4282037505 hasConceptScore W4282037505C99454951 @default.
- W4282037505 hasFunder F4320332163 @default.
- W4282037505 hasIssue "16_suppl" @default.
- W4282037505 hasLocation W42820375051 @default.
- W4282037505 hasOpenAccess W4282037505 @default.
- W4282037505 hasPrimaryLocation W42820375051 @default.
- W4282037505 hasRelatedWork W1998280666 @default.
- W4282037505 hasRelatedWork W2002708358 @default.
- W4282037505 hasRelatedWork W2068423195 @default.
- W4282037505 hasRelatedWork W2082392604 @default.
- W4282037505 hasRelatedWork W2194631636 @default.
- W4282037505 hasRelatedWork W2225497209 @default.
- W4282037505 hasRelatedWork W2290892674 @default.
- W4282037505 hasRelatedWork W2921643980 @default.
- W4282037505 hasRelatedWork W2970115840 @default.
- W4282037505 hasRelatedWork W3196456572 @default.
- W4282037505 hasVolume "40" @default.
- W4282037505 isParatext "false" @default.
- W4282037505 isRetracted "false" @default.
- W4282037505 workType "article" @default.